During the past decade, Biomedica Research Group conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 14 clinical trials were completed, i.e. on average, 87.5% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Biomedica Research Group" #1 sponsor was "Pfizer" with 5 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "ACADIA Pharmaceuticals Inc." with 2 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Biomedica Research Group" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "ClinIntel" with 1 trials as a collaborator, "Clinical Reference Laboratory" with 1 trials as a collaborator, "DSG EDC" with 1 trials as a collaborator and "Diamond Pharma Services Regulatory Affairs Consultancy" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Biomedica Research Group" are "Cardiovascular Disease" (3 trials), "Major Depressive Disorder" (3 trials), "Alzheimer Disease" (2 trials), "Alzheimer's Disease" (2 trials) and "Depressive Disorder, Major" (2 trials). Many other conditions were trialed in "Biomedica Research Group" in a lesser frequency.

Most popular intervention types in "Biomedica Research Group" are "Drug" (22 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Etrasimod" (3 trials), "Gantenerumab" (3 trials), "Seltorexant" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Biomedica Research Group" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Biomedica Research Group". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Biomedica Research Group, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Biomedica Research Group, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".